KRAS mutations (KRASm) have historically been difficult to target, and while a second-line targeted therapy for KRAS G12C NSCLC inhibitors like sotorasib and adagrasib are now approved, standard frontline treatment of KRASm metastatic NSCLC still consists of immunotherapy alone or in combination with chemotherapy [31]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.